Healthcare Nov 19, 2021 06:19 PM (GMT+8) · EqualOcean
Financial Associated Press, Nov. 19 (Reuters) - Tianshili announced that its holding subsidiary Tianshili biology transferred 0.3% of its shares in i-mab to Huatai capital at a total transfer price of US $12 million. After this transfer, the company's shareholding in i-mab will be reduced to 5.64%.
Related companies: